<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31929756</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1449-2288</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>2</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>International journal of biological sciences</Title><ISOAbbreviation>Int J Biol Sci</ISOAbbreviation></Journal><ArticleTitle>Nicotinamide Riboside Enhances Mitochondrial Proteostasis and Adult Neurogenesis through Activation of Mitochondrial Unfolded Protein Response Signaling in the Brain of ALS SOD1<sup>G93A</sup> Mice.</ArticleTitle><Pagination><StartPage>284</StartPage><EndPage>297</EndPage><MedlinePgn>284-297</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7150/ijbs.38487</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is caused by the progressive degeneration of motor neurons in the spinal cord, the brain stem, and the motor cortex. So far, there is still a lack of effective drugs. Nicotinamide adenine dinucleotide (NAD+) takes part in redox reactions and the NAD-dependent signaling pathway. The NAD+ decline is related with many neurological diseases, leading to the accumulation of neurotoxic protein in the central nervous system. Moreover, the NAD+ supplementation is shown to promote neural stem cells/neuronal precursor cells (NSCs/NPCs) pool maintenance. Regulatory mechanisms and functions of NAD+ metabolism in ALS are still unknown. Thus, we hypothesized the aggregation of human SOD1 toxic protein and the fate of NSCs/NPCs in the ALS disease could be improved by the administration of nicotinamide riboside (NR), an NAD+ precursor. In this study, we treated SOD1<sup>G93A</sup> transgenic and wild-type mice by the oral administration of 20 mg/ml NR starting at 50 days of age. Effects of NR on the body weight, the motor function, the onset and the survival were assessed during the experiment. The expression of mutant hSOD1 protein, mitochondrial unfolded protein response (UPR<sup>mt</sup>) related protein, mitophagy markers and NAD+ metabolism related protein were detected by immunoblotting. Effects of NR on the NSCs/NPCs in neurogenic niches of brain were identified by the immunofluorescence staining. Our investigation elucidated that the NR treatment exhibited better hanging wire endurance but did not postpone the onset or extend the life span of SOD1<sup>G93A</sup> mice. Besides, we observed that the NR repletion promoted the clearance of mitochondrial hSOD1 neurotoxic protein. Meanwhile, the mitochondrial function pathway was disrupted in the brain of SOD1<sup>G93A</sup> mice. What's more, we demonstrated that the inadequate function of NAD+ salvage synthesis pathway was the primary explanation behind the decline of NAD+, and the NR treatment enhanced the proliferation and migration of NSCs/NPCs in the brain of SOD1<sup>G93A</sup> mice. At last, we found that levels of UPR<sup>mt</sup> related protein were significantly increased in the brain of SOD1<sup>G93A</sup> mice after the NR treatment. In summary, these findings reveal that the administration of NR activates UPR<sup>mt</sup> signaling, modulates mitochondrial proteostasis and improves the adult neurogenesis in the brain of SOD1<sup>G93A</sup> mice.</AbstractText><CopyrightInformation>&#xa9; The author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Neurology, Jiangxi Provincial People's Hospital, Affiliated People's Hospital of Nanchang University, Nanchang 330006, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Jiangxi Provincial People's Hospital, Affiliated People's Hospital of Nanchang University, Nanchang 330006, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Weiwen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, Jiangxi Provincial People's Hospital, Affiliated People's Hospital of Nanchang University, Nanchang 330006, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wenzhi</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Renshi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Jiangxi Provincial People's Hospital, Affiliated People's Hospital of Nanchang University, Nanchang 330006, Jiangxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Int J Biol Sci</MedlineTA><NlmUniqueID>101235568</NlmUniqueID><ISSNLinking>1449-2288</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011726">Pyridinium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0I8H2M0L7N</RegistryNumber><NameOfSubstance UI="C018613">nicotinamide-beta-riboside</NameOfSubstance></Chemical><Chemical><RegistryNumber>25X51I8RD4</RegistryNumber><NameOfSubstance UI="D009536">Niacinamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Int J Biol Sci. 2022 Mar 3;18(5):2181-2183</RefSource><PMID Version="1">35342357</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058953" MajorTopicYN="N">Neural Stem Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009536" MajorTopicYN="N">Niacinamide</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011726" MajorTopicYN="N">Pyridinium Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056811" MajorTopicYN="N">Unfolded Protein Response</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Mitochondrial unfolded protein response related protein</Keyword><Keyword MajorTopicYN="N">Neural stem cells</Keyword><Keyword MajorTopicYN="N">Neuronal precursor cells</Keyword><Keyword MajorTopicYN="N">Nicotinamide riboside</Keyword></KeywordList><CoiStatement>Competing Interests: The authors have declared that no competing interest exists.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31929756</ArticleId><ArticleId IdType="pmc">PMC6949147</ArticleId><ArticleId IdType="doi">10.7150/ijbs.38487</ArticleId><ArticleId IdType="pii">ijbsv16p0284</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Canto C, Menzies KJ, Auwerx J. NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. Cell Metab. 2015;22:31&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4487780</ArticleId><ArticleId IdType="pubmed">26118927</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Su X, Quinn WJ 3rd, Hui S, Krukenberg K, Frederick DW. et al. Quantitative Analysis of NAD Synthesis-Breakdown Fluxes. Cell Metab. 2018;27:1067&#x2013;80. e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5932087</ArticleId><ArticleId IdType="pubmed">29685734</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu KW, Nandu T, Kim J, Challa S, DeBerardinis RJ, Kraus WL. Metabolic regulation of transcription through compartmentalized NAD(+) biosynthesis. Science. 2018;360:eaan. 5780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6465534</ArticleId><ArticleId IdType="pubmed">29748257</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaelin WG Jr McKnight SL. Influence of metabolism on epigenetics and disease. Cell. 2013;153:56&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3775362</ArticleId><ArticleId IdType="pubmed">23540690</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsyuba E, Auwerx J. Modulating NAD(+) metabolism, from bench to bedside. EMBO J. 2017;36:2670&#x2013;2683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5599801</ArticleId><ArticleId IdType="pubmed">28784597</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdin E. NAD(+) in aging, metabolism, and neurodegeneration. Science. 2015;350:1208&#x2013;1213.</Citation><ArticleIdList><ArticleId IdType="pubmed">26785480</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills KF, Yoshida S, Stein LR, Grozio A, Kubota S, Sasaki Y. et al. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell Metab. 2016;24:795&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5668137</ArticleId><ArticleId IdType="pubmed">28068222</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu XH, Lu M, Lee BY, Ugurbil K, Chen W. In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. P Natl Acad Sci U S A. 2015;112:2876&#x2013;2881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4352772</ArticleId><ArticleId IdType="pubmed">25730862</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadenbach B. Introduction to mitochondrial oxidative phosphorylation. Adv Exp Med Biol. 2012;748:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">22729852</ArticleId></ArticleIdList></Reference><Reference><Citation>Golpich M, Amini E, Mohamed Z, Azman Ali R, Mohamed Ibrahim N, Ahmadiani A. Mitochondrial Dysfunction and Biogenesis in Neurodegenerative diseases: Pathogenesis and Treatment. CNS Neurosci Ther. 2017;23:5&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6492703</ArticleId><ArticleId IdType="pubmed">27873462</ArticleId></ArticleIdList></Reference><Reference><Citation>Durand F, Hoogenraad N. Assessing Mitochondrial Unfolded Protein Response in Mammalian Cells. Methods Mol Biol. 2017;1567:363&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">28276030</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson TM, Dawson VL. Mitochondrial Mechanisms of Neuronal Cell Death: Potential Therapeutics. Annu Rev Pharmacol Toxicol. 2017;57:437&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">28061689</ArticleId></ArticleIdList></Reference><Reference><Citation>de Castro IP, Martins LM, Loh SH. Mitochondrial quality control and Parkinson's disease: a pathway unfolds. Mol Neurobiol. 2011;43:80&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3062764</ArticleId><ArticleId IdType="pubmed">21120708</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrentino V, Romani M, Mouchiroud L, Beck JS, Zhang H, D'Amico D. et al. Enhancing mitochondrial proteostasis reduces amyloid-beta proteotoxicity. Nature. 2017;552:187&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5730497</ArticleId><ArticleId IdType="pubmed">29211722</ArticleId></ArticleIdList></Reference><Reference><Citation>Callegari S, Dennerlein S. Sensing the Stress: A Role for the UPR(mt) and UPR(am) in the Quality Control of Mitochondria. Front Cell Dev Biol. 2018;6:31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5882792</ArticleId><ArticleId IdType="pubmed">29644217</ArticleId></ArticleIdList></Reference><Reference><Citation>Moehle EA, Shen K, Dillin A. Mitochondrial proteostasis in the context of cellular and organismal health and aging. J Biol Chem. 2019;294:5396&#x2013;5407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6462515</ArticleId><ArticleId IdType="pubmed">29622680</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen MB, Jasper H. Mitochondrial proteostasis in the control of aging and longevity. Cell Metab. 2014;20:214&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4274350</ArticleId><ArticleId IdType="pubmed">24930971</ArticleId></ArticleIdList></Reference><Reference><Citation>Camacho-Pereira J, Tarrago MG, Chini CCS, Nin V, Escande C, Warner GM. et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016;23:1127&#x2013;1139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4911708</ArticleId><ArticleId IdType="pubmed">27304511</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JB, Kubota S, Ban N, Yoshida M, Santeford A, Sene A. et al. NAMPT-Mediated NAD(+) Biosynthesis Is Essential for Vision In Mice. Cell Rep. 2016;17:69&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5104206</ArticleId><ArticleId IdType="pubmed">27681422</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Ryu D, Wu Y, Gariani K, Wang X, Luan P. et al. NAD(+) repletion improves mitochondrial and stem cell function and enhances life span in mice. Science. 2016;352:1436&#x2013;1443.</Citation><ArticleIdList><ArticleId IdType="pubmed">27127236</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein LR, Imai S. Specific ablation of Nampt in adult neural stem cells recapitulates their functional defects during aging. EMBO J. 2014;33:1321&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4194122</ArticleId><ArticleId IdType="pubmed">24811750</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou Y, Lautrup S, Cordonnier S, Wang Y, Croteau DL, Zavala E. et al. NAD(+) supplementation normalizes key Alzheimer's features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency. Proc Natl Acad Sci U S A. 2018;115:E1876&#x2013;E1885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5828618</ArticleId><ArticleId IdType="pubmed">29432159</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A. et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Jones A, Troakes C, King A, Al-Sarraj S, van den Berg LH. The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol. 2012;124:339&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">22903397</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravits J, Appel S, Baloh RH, Barohn R, Brooks BR, Elman L. et al. Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:S5&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779649</ArticleId><ArticleId IdType="pubmed">23678876</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD. et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. An outcome study of riluzole in amyotrophic lateral sclerosis-a population-based study in Ireland, 1996-2000. J Neurol. 2003;250:473&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">12700914</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD. Edaravone: A new drug approved for ALS. Cell. 2017;171:725.</Citation><ArticleIdList><ArticleId IdType="pubmed">29100067</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A, Khan R, Polymenidou M, Schulz PE. Disease-modifying effects of metabolic perturbations in ALS/FTLD. Mol Neurodegener. 2018;13:63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6278047</ArticleId><ArticleId IdType="pubmed">30509290</ArticleId></ArticleIdList></Reference><Reference><Citation>Tafuri F, Ronchi D, Magri F, Comi GP, Corti S. SOD1 misplacing and mitochondrial dysfunction in amyotrophic lateral sclerosis pathogenesis. Front Cell Neurosci. 2015;9:336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4548205</ArticleId><ArticleId IdType="pubmed">26379505</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Martin LJ. The adult neural stem and progenitor cell niche is altered in amyotrophic lateral sclerosis mouse brain. J Comp Neurol. 2006;497:468&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">16736475</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi L, Gan L, Luo C, Lien L, Liu R. Temporal response of neural progenitor cells to disease onset and progression in amyotrophic lateral sclerosis-like transgenic mice. Stem Cells Dev. 2007;16:579&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pubmed">17784831</ArticleId></ArticleIdList></Reference><Reference><Citation>Harlan BA, Pehar M, Sharma DR, Beeson G, Beeson CC, Vargas MR. Enhancing NAD+ Salvage Pathway Reverts the Toxicity of Primary Astrocytes Expressing Amyotrophic Lateral Sclerosis-linked Mutant Superoxide Dismutase 1 (SOD1) J Biol Chem. 2016;291:10836&#x2013;10846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4865928</ArticleId><ArticleId IdType="pubmed">27002158</ArticleId></ArticleIdList></Reference><Reference><Citation>Ocampo A, Liu J, Barrientos A. NAD+ salvage pathway proteins suppress proteotoxicity in yeast models of neurodegeneration by promoting the clearance of misfolded/oligomerized proteins. Hum Mol Genet. 2013;22:1699&#x2013;1708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3657478</ArticleId><ArticleId IdType="pubmed">23335597</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Zhang Q, Bao R, Zhang N, Wang Y, Polo-Parada L. et al. Deletion of Nampt in Projection Neurons of Adult Mice Leads to Motor Dysfunction, Neurodegeneration, and Death. Cell Rep. 2017;20:2184&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6021762</ArticleId><ArticleId IdType="pubmed">28854367</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Chan NY, Sauve AA. Syntheses of nicotinamide riboside and derivatives: effective agents for increasing nicotinamide adenine dinucleotide concentrations in mammalian cells. J Med Chem. 2007;50:6458&#x2013;6461.</Citation><ArticleIdList><ArticleId IdType="pubmed">18052316</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, Bendotti C, Blaugrund E, Hengerer B, L&#xf6;ffler JP, Martin J. et al. Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop. Amyotroph Lateral Scler. 2007;8:217&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">17653919</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K, Kelly N. et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler. 2008;9:4&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">18273714</ArticleId></ArticleIdList></Reference><Reference><Citation>Crapo JD, Oury T, Rabouille C, Slot JW, Chang LY. Copper,zinc superoxide dismutase is primarily a cytosolic protein in human cells. Proc Natl Acad Sci U S A. 1992;89:10405&#x2013;10409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC50347</ArticleId><ArticleId IdType="pubmed">1332049</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Y, Wang J, Henderson MJ, Yang P, Hagen BM, Siddique T. et al. Nuclear export of misfolded SOD1 mediated by a normally buried NES-like sequence reduces proteotoxicity in the nucleus. eLife. 2017;6:e23759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5449186</ArticleId><ArticleId IdType="pubmed">28463106</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattiazzi M, D'Aurelio M, Gajewski CD, Martushova K, Kiaei M, Beal MF. et al. Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J Biol Chem. 2002;277:29626&#x2013;29633.</Citation><ArticleIdList><ArticleId IdType="pubmed">12050154</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Lillo C, Jonsson PA, Vande Velde C, Ward CM, Miller TM. et al. Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron. 2004;43:5&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">15233913</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng HX, Shi Y, Furukawa Y, Zhai H, Fu R, Liu E. et al. Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria. Proc Natl Acad Sci U S A. 2006;103:7142&#x2013;7147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1447523</ArticleId><ArticleId IdType="pubmed">16636275</ArticleId></ArticleIdList></Reference><Reference><Citation>Vande Velde C, Miller TM, Cashman NR, Cleveland DW. Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria. Proc Natl Acad Sci U S A. 2008;105:4022&#x2013;4027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268797</ArticleId><ArticleId IdType="pubmed">18296640</ArticleId></ArticleIdList></Reference><Reference><Citation>Israelson A, Arbel N, Da Cruz S, Ilieva H, Yamanaka K, Shoshan-Barmatz V. et al. Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Neuron. 2010;67:575&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2941987</ArticleId><ArticleId IdType="pubmed">20797535</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomo GM, Manfredi G. Exploring new pathways of neurodegeneration in ALS: the role of mitochondria quality control. Brain Res. 2015;1607:36&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4385426</ArticleId><ArticleId IdType="pubmed">25301687</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EF, Shaw PJ, De Vos KJ. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci Lett; 2017. S0304-3940(17)30544-X.</Citation></Reference><Reference><Citation>Trammell SA, Yu L, Redpath P, Migaud ME, Brenner C. Nicotinamide Riboside Is a Major NAD+ Precursor Vitamin in Cow Milk. J Nutr. 2016;146:957&#x2013;963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6879052</ArticleId><ArticleId IdType="pubmed">27052539</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang EF, Lautrup S, Hou Y, Demarest TG, Croteau DL, Mattson MP. et al. NAD(+) in Aging: Molecular Mechanisms and Translational Implications. Trends Mol Med. 2017;23:899&#x2013;916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7494058</ArticleId><ArticleId IdType="pubmed">28899755</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouchiroud L, Houtkooper RH, Moullan N, Katsyuba E, Ryu D, Canto C. et al. The NAD(+)/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling. Cell. 2013;154:430&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753670</ArticleId><ArticleId IdType="pubmed">23870130</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Oh GS, Shen A, Lee SB, Choe SK, Kwon KB. et al. Augmentation of NAD(+) by NQO1 attenuates cisplatin-mediated hearing impairment. Cell Death Dis. 2014;5:e1292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4611728</ArticleId><ArticleId IdType="pubmed">24922076</ArticleId></ArticleIdList></Reference><Reference><Citation>Son MJ, Kwon Y, Son T, Cho YS. Restoration of Mitochondrial NAD(+) Levels Delays Stem Cell Senescence and Facilitates Reprogramming of Aged Somatic Cells. Stem Cells. 2016;34:2840&#x2013;2851.</Citation><ArticleIdList><ArticleId IdType="pubmed">27428041</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond AM, Ming GL, Song H. Adult Mammalian Neural Stem Cells and Neurogenesis: Five Decades Later. Cell Stem Cell. 2015;17:385&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4683085</ArticleId><ArticleId IdType="pubmed">26431181</ArticleId></ArticleIdList></Reference><Reference><Citation>Cluskey S, Ramsden DB. Mechanisms of neurodegeneration in amyotrophic lateral sclerosis. Mol Pathol. 2001;54:386&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1187128</ArticleId><ArticleId IdType="pubmed">11724913</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandya RS, Mao LL, Zhou EW, Bowser R, Zhu Z, Zhu Y. et al. Neuroprotection for amyotrophic lateral sclerosis: role of stem cells, growth factors, and gene therapy. Cent Nerv Syst Agents Med Chem. 2012;12:15&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4170803</ArticleId><ArticleId IdType="pubmed">22283698</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Fotinos A, Mao LL, Atassi N, Zhou EW, Ahmad S. et al. Neuroprotective agents target molecular mechanisms of disease in ALS. Drug Discov Today. 2015;20:65&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">25205348</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz J. Disease-modifying treatment of amyotrophic lateral sclerosis. Am J Manag Care. 2018;24:S327&#x2013;S35.</Citation><ArticleIdList><ArticleId IdType="pubmed">30207671</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal MK. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019;39:733&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Vande Velde C, McDonald KK, Boukhedimi Y, McAlonis-Downes M, Lobsiger CS, Bel Hadj S. et al. Misfolded SOD1 associated with motor neuron mitochondria alters mitochondrial shape and distribution prior to clinical onset. PloS one. 2011;6:e22031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136936</ArticleId><ArticleId IdType="pubmed">21779368</ArticleId></ArticleIdList></Reference><Reference><Citation>Belenky P, Racette FG, Bogan KL, McClure JM, Smith JS, Brenner C. Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD+ Cell. 2007;129:473&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">17482543</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Yang T, Baur JA, Perez E, Matsui T, Carmona JJ. et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell. 2007;130:1095&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3366687</ArticleId><ArticleId IdType="pubmed">17889652</ArticleId></ArticleIdList></Reference><Reference><Citation>Cambronne XA, Stewart ML, Kim D, Jones-Brunette AM, Morgan RK, Farrens DL. et al. Biosensor reveals multiple sources for mitochondrial NAD(+) Science. 2016;352:1474&#x2013;1477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6530784</ArticleId><ArticleId IdType="pubmed">27313049</ArticleId></ArticleIdList></Reference><Reference><Citation>Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC. et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 2009;458:1056&#x2013;1060.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3616311</ArticleId><ArticleId IdType="pubmed">19262508</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Hu Q, Cheng F, Su N, Wang A, Zou Y. et al. SoNar, a Highly Responsive NAD+/NADH Sensor, Allows High-Throughput Metabolic Screening of Anti-tumor Agents. Cell Metab. 2015;21:777&#x2013;789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4427571</ArticleId><ArticleId IdType="pubmed">25955212</ArticleId></ArticleIdList></Reference><Reference><Citation>Frederick DW, Loro E, Liu L, Davila A Jr, Chellappa K, Silverman IM. et al. Loss of NAD Homeostasis Leads to Progressive and Reversible Degeneration of Skeletal Muscle. Cell Metab. 2016;24:269&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4985182</ArticleId><ArticleId IdType="pubmed">27508874</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava S. Emerging therapeutic roles for NAD(+) metabolism in mitochondrial and age-related disorders. Clin Transl Med. 2016;5:25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4963347</ArticleId><ArticleId IdType="pubmed">27465020</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino J, Baur JA, Imai SI. NAD(+) Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metab. 2018;27:513&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5842119</ArticleId><ArticleId IdType="pubmed">29249689</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Yang Y, Liang W, Wang T, Wang S, Wang X. et al. Neuroprotection by urate on the mutant hSOD1-related cellular and Drosophila models of amyotrophic lateral sclerosis: Implication for GSH synthesis via activating Akt/GSK3beta/Nrf2/GCLC pathways. Brain Res Bull. 2019;146:287&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">30690059</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieganowski P, Brenner C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell. 2004;117:495&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">15137942</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong B, Pan Y, Vempati P, Zhao W, Knable L, Ho L. et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol Aging. 2013;34:1581&#x2013;1588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3632303</ArticleId><ArticleId IdType="pubmed">23312803</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown KD, Maqsood S, Huang JY, Pan Y, Harkcom W, Li W. et al. Activation of SIRT3 by the NAD(+) precursor nicotinamide riboside protects from noise-induced hearing loss. Cell Metab. 2014;20:1059&#x2013;1068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4940130</ArticleId><ArticleId IdType="pubmed">25470550</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamity MV, White SR, Walder RY, Schmidt MS, Brenner C, Hammond DL. Nicotinamide riboside, a form of vitamin B3 and NAD+ precursor, relieves the nociceptive and aversive dimensions of paclitaxel-induced peripheral neuropathy in female rats. Pain. 2017;158:962&#x2013;972.</Citation><ArticleIdList><ArticleId IdType="pubmed">28346814</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaturvedi P, Tyagi SC. NAD(+): A big player in cardiac and skeletal muscle remodeling and aging. J Cell Physiol. 2018;233:1895&#x2013;1896.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5694390</ArticleId><ArticleId IdType="pubmed">28518407</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu D, Zhang H, Ropelle ER, Sorrentino V, Mazala DA, Mouchiroud L. et al. NAD+ repletion improves muscle function in muscular dystrophy and counters global PARylation. Sci Transl Med. 2016;8:361ra139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5535761</ArticleId><ArticleId IdType="pubmed">27798264</ArticleId></ArticleIdList></Reference><Reference><Citation>Maynard S, Fang EF, Scheibye-Knudsen M, Croteau DL, Bohr VA. DNA Damage, DNA Repair, Aging, and Neurodegeneration. Cold Spring Harb Perspect Med. 2015;5:a025130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4588127</ArticleId><ArticleId IdType="pubmed">26385091</ArticleId></ArticleIdList></Reference><Reference><Citation>White RR, Vijg J. Do DNA Double-Strand Breaks Drive Aging? Mol Cell. 2016;63:729&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5012315</ArticleId><ArticleId IdType="pubmed">27588601</ArticleId></ArticleIdList></Reference><Reference><Citation>Galan L, Gomez-Pinedo U, Guerrero A, Garcia-Verdugo JM, Matias-Guiu J. Amyotrophic lateral sclerosis modifies progenitor neural proliferation in adult classic neurogenic brain niches. BMC Neurol. 2017;17:173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585932</ArticleId><ArticleId IdType="pubmed">28874134</ArticleId></ArticleIdList></Reference><Reference><Citation>Nacarelli T, Lau L, Fukumoto T, Zundell J, Fatkhutdinov N, Wu S. et al. NAD(+) metabolism governs the proinflammatory senescence-associated secretome. Nat Cell Biol. 2019;21:397&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6448588</ArticleId><ArticleId IdType="pubmed">30778219</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>